MSA prions exhibit remarkable stability and resistance to inactivation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
In multiple system atrophy (MSA), progressive neurodegeneration results from the protein α-synuclein misfolding into a self-templating prion conformation that spreads throughout the brain. MSA prions are transmissible to transgenic (Tg) mice expressing mutated human α-synuclein (TgM83+/−), inducing neurological disease following intracranial inoculation with brain homogenate from deceased patient samples. Noting the similarities between α-synuclein prions and PrP scrapie (PrPSc) prions responsible for Creutzfeldt–Jakob disease (CJD), we investigated MSA transmission under conditions known to result in PrPSc transmission. When peripherally exposed to MSA via the peritoneal cavity, hind leg muscle, and tongue, TgM83+/− mice developed neurological signs accompanied by α-synuclein prions in the brain. Iatrogenic CJD, resulting from PrPSc prion adherence to surgical steel instruments, has been investigated by incubating steel sutures in contaminated brain homogenate before implantation into mouse brain. Mice studied using this model for MSA developed disease, whereas wire incubated in control homogenate had no effect on the animals. Notably, formalin fixation did not inactivate α-synuclein prions. Formalin-fixed MSA patient samples also transmitted disease to TgM83+/− mice, even after incubating in fixative for 244 months. Finally, at least 10% sarkosyl was found to be the concentration necessary to partially inactivate MSA prions. These results demonstrate the robustness of α-synuclein prions to denaturation. Moreover, they establish the parallel characteristics between PrPSc and α-synuclein prions, arguing that clinicians should exercise caution when working with materials that might contain α-synuclein prions to prevent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140 · cited 1×
“7 per 100,000 individuals annually [13, 45], MSA is characterized by rapidly progressing autonomic dysfunction and motor deficits presenting as either cerebellar symptoms or parkinsonism [22].”
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130 · cited 1×
“The existence of two distinct strains of α-synuclein prions in MSA and PD patients is consistent with work published by others demonstrating that α-synuclein misfolding into distinct conformations produces differing physiological effects [5, 37].”
Papp, M. I., Kahn, J. E., & Lantos, P. L. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90219-0 · Cited by 991 · cited 2×
“MSA is a neurodegenerative disease resulting in the accumulation of glial cytoplasmic inclusions (GCIs) in oligodendrocytes [36].”
Prion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Tu, P., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., & Lee, V. M. ‐. (1998) · Annals of Neurology · doi:10.1002/ana.410440324 · Cited by 686 · cited 1×
“Despite the identification of GCIs as the neuropathological hallmark of MSA in 1989 [36], α-synuclein was not recognized as the primary protein component until 1998 [44, 49, 50].”
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643 · cited 1×
“Despite the identification of GCIs as the neuropathological hallmark of MSA in 1989 [36], α-synuclein was not recognized as the primary protein component until 1998 [44, 49, 50].”
Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis
Eisele, Y. S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S. A., Wolburg, H., Walker, L. C., Staufenbiel, M., Heikenwalder, M., & Jucker, M. (2010) · Science · doi:10.1126/science.1194516 · Cited by 568
Lowe, J., Blanchard, A., Morrell, K., Lennox, G., Reynolds, L., Billett, M., Landon, M., & Mayer, R. J. (1988) · The Journal of Pathology · doi:10.1002/path.1711550105 · Cited by 539
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., Launchbury, F., Linehan, J., Richard-Loendt, A., Walker, A. S., et al. (2015) · Nature · doi:10.1038/nature15369 · Cited by 518 · cited 1×
“1 3 dura mater grafts showed some patients also developed Aβ plaques earlier than age-matched controls [17, 25, 28].”
Cited by
Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0238-6 · Cited by 450
Initiation and propagation of α-synuclein aggregation in the nervous system
Hijaz, B. A., & Volpicelli-Daley, L. A. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00368-6 · Cited by 262
Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy
Jellinger, K. A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170397 · Cited by 208
“that spreads throughout the brain [491].”
BackgroundAlpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles
Bernal-Conde, L. D., Ramos-Acevedo, R., Reyes-Hernández, M. A., Balbuena-Olvera, A. J., Morales-Moreno, I. D., Argüero-Sánchez, R., Schüle, B., & Guerra-Crespo, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01399 · Cited by 189
“Similar results can be found when the rat is exposed peripherally (like peritoneal cavity) to the homogenates of MSA brains (Woerman et al., 2018).”
ResultAlpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
Brás, I. C., & Outeiro, T. F. (2021) · Cells · doi:10.3390/cells10020375 · Cited by 136
Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration
Sorrentino, Z. A., Xia, Y., Funk, C., Riffe, C. J., Rutherford, N. J., Ceballos Diaz, C., Sacino, A. N., Price, N. D., Golde, T. E., Giasson, B. I., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.005 · Cited by 54
Carlson, G. A., & Prusiner, S. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094861 · Cited by 51
Self-citationSarkosyl differentially solubilizes patient-derived alpha-synuclein fibril strains
Gram, H., Theologidis, V., Boesen, T., & Jensen, P. H. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1177556 · Cited by 7
Metadata
- Authors
- Woerman, A. L., Kazmi, S. A., Patel, S., Freyman, Y., Oehler, A., Aoyagi, A., Mordes, D. A., Halliday, G. M., Middleton, L. T., Gentleman, S. M., Olson, S. H., & Prusiner, S. B.
- Venue
- Acta Neuropathologica
- Published
- 2017-08-28
- Volume
- 135
- Issue
- 1
- Pages
- 49-63
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2749912201
- Cited by
- 95
- References
- 13
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.